Substituted arylsulfonamides as antiviral agents
The invention relates to substituted arylsulfonamides of formula (I) and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.
1. A compound of formula
in which
A represents a group of formula
whereby
* is the linkage site to the carbon atom of the pyridinyl ring, and
# is the linkage site to the carbon atom of the phenyl ring,
R 1 represents hydrogen, amino or methylcarbonylamino,
R 2 represents hydrogen or halogen,
R 3 represents hydrogen, halogen or cyano,
R 4 represents hydrogen, halogen or cyano,
R 5 represents hydrogen or halogen,
R 6 represents hydrogen or halogen,
R 7 represents hydrogen, halogen or C 1 -C 3 -alkyl, and
R 8 represents hydrogen, halogen or C 1 -C 3 -alkyl,
or one of its salts.
2. The compound of claim 1 , whereby
A represents a group of formula
whereby
* is the linkage site to the carbon atom of the pyridinyl ring, and
# is the linkage site to the carbon atom of the phenyl ring,
R 1 represents hydrogen, amino or methylcarbonylamino,
R 2 , R 3 and R 4 each represent hydrogen,
R 5 represents hydrogen or halogen,
R 6 represents hydrogen or halogen, and
R 7 and R 8 each represent hydrogen,
or one of its salts.
3. The compound of claim 1 , whereby
A represents a group of formula
whereby
* is the linkage site to the carbon atom of the pyridinyl ring, and
# is the linkage site to the carbon atom of the phenyl ring,
R 1 represents amino or methylcarbonylamino,
R 2 , R 3 and R 4 each represent hydrogen,
R 5 represents hydrogen,
R 6 represents hydrogen or halogen, and
R 7 and R 8 each represent hydrogen,
or one of its salts.
4. A method for the preparation of a compound of formula (I) of claim 1 , comprising reacting a compound of formula
in which
A, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the meaning indicated in claim 1 , with a compound of formula
in which
R 7 and R 8 have the meaning indicated in claim 1 , and
X 1 represents halogen or hydroxy.
5. A medicament comprising a therapeutically effective amount of a compound of claim 1 in combination with an inert, non-toxic, pharmaceutically acceptable excipient.
6. A method for the production of a medicament for the treatment of viral infections, comprising mixing a therapeutically effective amount of a compound of claim 1 with at least one pharmaceutically acceptable excipient, wherein the viral infection is an infection with the human cytomegalovirus (HCMV) or another representative of the group of herpes viridae.
7. A method of controlling viral infections in humans and animals by administering an antivirally effective amount of at least one compound of claim 1 , wherein the viral infection is an infection with the human cytomegalovirus (HCMV) or another representative of the group of herpes viridae.
8. The method of claim 4 , wherein X 1 is chlorine, bromine, or hydroxy.